Investment Opportunities from Innovations in Cancer Treatment
Wednesday February 24, 2016
In the past decade, there have been significant breakthroughs in cancer research through advances in immuno-oncology, a therapeutic approach that uses the body’s immune system to fight cancer. Sales of the new immuno-oncology drugs launched last year have crossed $1bn. This issue was brought back into the public focus again after President Obama’s State of the Union address reflecting renewed interest in the innovations in cancer research and implications for investors.
Much is changing in cancer research and scientific progress in diagnosis and treatment, which has led to a better outlook for cancer patients. Pharmaceutical companies with exposure to oncology have offered better earnings growth and high returns on capital and smaller biotech companies with no prior history have also entered the fray. This session will address the questions on top of investors’ minds including anticipated advancement in cancer research and immunotherapy, sector views and investment implications as well as due-diligence guidelines for investors.
This event will:
Give you a more in-depth look at the innovations in cancer research and the methods of analyzing and investing in them
Who should attend?
Portfolio managers and research analysts, hedge funds, mutual funds, private equity firms and service providers such as attorneys, consultants, and rating agency personnel.
CFA Society New York expects all attendees to comply with CFA Society New York’s Code of Conduct while attending CFA Society New York events or meetings. CFA Society New York expressly reserves the right, in its sole discretion, to grant or deny access to any individual, or to expel any individual from any CFA Society New York event or meeting.